Drug information provided by: Merative, Micromedex®
Midostaurin is used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy to treat newly diagnosed acute myeloid leukemia (AML) in patients who are FLT3 mutation-positive. Your doctor will perform a test to check for this mutation before you use this medicine.
This medicine is also used to treat aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms:
Portions of this document last updated: June 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift now and help create new and better solutions for more than 1.3 million patients who turn to Mayo Clinic each year.